Insmed (INSM) is back in focus after recent trading pulled the stock down about 21% over the past month and roughly 33% over the past 3 months, prompting fresh attention on its rare disease portfolio.

At a share price of US$106.24, Insmed has seen short term momentum fade, with the 30 day share price return down 21.4% and the year to date share price return down 40%, even though the 1 year total shareholder return is 57.3% and the 3 year total shareholder return is very large.

If you are comparing Insmed with other opportunities in high growth therapies and medical technology, it can be useful to scan a broader set of healthcare focused ideas using 34 healthcare AI stocks

With Insmed’s stock retreating after a strong multi year run, the key question now is whether the current US$106.24 price reflects a discount relative to its rare disease pipeline, or if the market is already pricing in future growth?

Most Popular Narrative: 50% Undervalued

At around $106, the most widely followed narrative anchors on a fair value of $212.50, creating a wide gap that hinges on future respiratory launches.

The analysts have a consensus price target of $212.5 for Insmed based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $243.0, and the most bearish reporting a price target of just $177.0.

Want to see what supports a valuation roughly double the current share price? Revenue expansion, margin shifts and a future earnings profile sit at the core of this narrative, along with a higher required return baked into the model.

Result: Fair Value of $212.50 (UNDERVALUED)

However, this hinges on brensocatib approvals and uptake. Any FDA delays or payer pushback on reimbursement could quickly challenge the idea that Insmed is 50% undervalued.

Another Way Of Looking At Valuation

Those analyst-driven fair values around $212.50 frame Insmed as heavily undervalued, but the current P/S of 28.1x tells a tougher story. It is far above the US Biotechs industry at 10.7x and the 16.5x fair ratio, which points to meaningful valuation risk if sentiment cools.

To see what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern feels familiar, that is exactly why you should review the data yourself and decide where you stand. You can start with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Insmed is on your radar, do not stop there, widening your watchlist with fresh ideas can help you spot opportunities you might otherwise miss.

• Spot potential bargains early by scanning 48 high quality undervalued stocks with solid fundamentals and room for reassessment.
• Prioritise resilience by reviewing 69 resilient stocks with low risk scores that screen well on financial strength and risk metrics.
• Hunt for underfollowed opportunities through the screener containing 21 high quality undiscovered gems before others start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.